Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.85
AMGN's Cash to Debt is ranked higher than
55% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. AMGN: 0.85 )
AMGN' s 10-Year Cash to Debt Range
Min: 0.27   Max: 8.25
Current: 0.85

0.27
8.25
Equity to Asset 0.36
AMGN's Equity to Asset is ranked higher than
56% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMGN: 0.36 )
AMGN' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.84
Current: 0.36

0.33
0.84
F-Score: 5
Z-Score: 2.55
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 29.98
AMGN's Operating margin (%) is ranked higher than
95% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. AMGN: 29.98 )
AMGN' s 10-Year Operating margin (%) Range
Min: -14.21   Max: 43.12
Current: 29.98

-14.21
43.12
Net-margin (%) 24.74
AMGN's Net-margin (%) is ranked higher than
95% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. AMGN: 24.74 )
AMGN' s 10-Year Net-margin (%) Range
Min: -25.2   Max: 34.22
Current: 24.74

-25.2
34.22
ROE (%) 21.01
AMGN's ROE (%) is ranked higher than
96% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. AMGN: 21.01 )
AMGN' s 10-Year ROE (%) Range
Min: -11.85   Max: 39.26
Current: 21.01

-11.85
39.26
ROA (%) 7.39
AMGN's ROA (%) is ranked higher than
92% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. AMGN: 7.39 )
AMGN' s 10-Year ROA (%) Range
Min: -9.01   Max: 28.29
Current: 7.39

-9.01
28.29
ROC (Joel Greenblatt) (%) 74.09
AMGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. AMGN: 74.09 )
AMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -29.14   Max: 94.09
Current: 74.09

-29.14
94.09
Revenue Growth (%) 16.10
AMGN's Revenue Growth (%) is ranked higher than
88% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. AMGN: 16.10 )
AMGN' s 10-Year Revenue Growth (%) Range
Min: 5.9   Max: 29.3
Current: 16.1

5.9
29.3
EBITDA Growth (%) 9.20
AMGN's EBITDA Growth (%) is ranked higher than
85% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. AMGN: 9.20 )
AMGN' s 10-Year EBITDA Growth (%) Range
Min: 1.1   Max: 25.3
Current: 9.2

1.1
25.3
EPS Growth (%) 11.50
AMGN's EPS Growth (%) is ranked higher than
86% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. AMGN: 11.50 )
AMGN' s 10-Year EPS Growth (%) Range
Min: 1.2   Max: 28.2
Current: 11.5

1.2
28.2
» AMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AMGN Guru Trades in Q4 2013

Joel Greenblatt 23,170 sh (New)
Paul Tudor Jones 7,697 sh (New)
Ray Dalio 7,513 sh (New)
Jim Simons 862,245 sh (+1114.43%)
Steven Cohen 751,083 sh (+1086.86%)
Jeremy Grantham 3,122,746 sh (+17.01%)
Mario Gabelli 23,620 sh (+5.35%)
Ken Fisher 5,837 sh (+3.64%)
Stanley Druckenmiller 231,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments 694,971 sh (-0.16%)
PRIMECAP Management 35,508,354 sh (-0.85%)
Mark Hillman 7,912 sh (-1.95%)
Bill Frels 10,780 sh (-3.58%)
Dodge & Cox 136,620 sh (-14.64%)
Vanguard Health Care Fund 8,775,155 sh (-18.43%)
Alan Fournier 70,000 sh (-22.22%)
John Hussman 175,000 sh (-30%)
» More
Q1 2014

AMGN Guru Trades in Q1 2014

RS Investment Management 3,840 sh (New)
Louis Moore Bacon 3,450 sh (New)
Ken Fisher 49,887 sh (+754.67%)
Alan Fournier 150,000 sh (+114.29%)
Mario Gabelli 32,565 sh (+37.87%)
Pioneer Investments 783,138 sh (+12.69%)
Jeremy Grantham 3,290,249 sh (+5.36%)
Bill Frels 10,780 sh (unchged)
Stanley Druckenmiller Sold Out
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Vanguard Health Care Fund 8,213,855 sh (-6.4%)
PRIMECAP Management 32,161,744 sh (-9.42%)
John Hussman 150,000 sh (-14.29%)
Dodge & Cox 105,757 sh (-22.59%)
Paul Tudor Jones 3,985 sh (-48.23%)
Jim Simons 333,349 sh (-61.34%)
Steven Cohen 13,665 sh (-98.18%)
» More
Q2 2014

AMGN Guru Trades in Q2 2014

John Buckingham 56,216 sh (New)
Daniel Loeb 450,000 sh (New)
Joel Greenblatt 9,938 sh (New)
Paul Tudor Jones 9,013 sh (+126.17%)
Mario Gabelli 60,335 sh (+85.28%)
Ken Fisher 85,316 sh (+71.02%)
Alan Fournier 236,000 sh (+57.33%)
Bill Frels 10,991 sh (+1.96%)
Steven Cohen 238,008 sh (unchged)
RS Investment Management 3,840 sh (unchged)
Louis Moore Bacon 3,450 sh (unchged)
Jeremy Grantham 3,260,920 sh (-0.89%)
PRIMECAP Management 31,853,844 sh (-0.96%)
Vanguard Health Care Fund 8,049,455 sh (-2%)
Jim Simons 310,645 sh (-6.81%)
Dodge & Cox 85,857 sh (-18.82%)
John Hussman 50,000 sh (-66.67%)
Pioneer Investments 142,948 sh (-81.75%)
» More
Q3 2014

AMGN Guru Trades in Q3 2014

Jean-Marie Eveillard 714,178 sh (New)
Stanley Druckenmiller 158,900 sh (New)
Ruane Cunniff 1,617 sh (New)
Daniel Loeb 1,325,000 sh (+194.44%)
Ken Fisher 156,629 sh (+83.59%)
John Buckingham 56,921 sh (+1.25%)
RS Investment Management 3,840 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
PRIMECAP Management 31,793,873 sh (-0.19%)
Bill Frels 10,941 sh (-0.45%)
Mario Gabelli 59,950 sh (-0.64%)
Vanguard Health Care Fund 7,022,755 sh (-12.75%)
Jim Simons 268,445 sh (-13.58%)
Dodge & Cox 72,907 sh (-15.08%)
Pioneer Investments 108,816 sh (-23.88%)
Alan Fournier 160,000 sh (-32.2%)
Jeremy Grantham 1,992,020 sh (-38.91%)
John Hussman 25,000 sh (-50%)
Paul Tudor Jones 3,300 sh (-63.39%)
Joel Greenblatt 2,693 sh (-72.9%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Daniel Loeb 2014-09-30 Add 194.44%1.39%$115.39 - $144.01 $ 162.8125%1325000
Vanguard Health Care Fund 2014-09-30 Reduce -12.75%0.32%$115.39 - $144.01 $ 162.8125%7022755
Jean-Marie Eveillard 2014-09-30 New Buy0.25%$115.39 - $144.01 $ 162.8125%714178
John Hussman 2014-09-30 Reduce -50%0.23%$115.39 - $144.01 $ 162.8125%25000
Ken Fisher 2014-09-30 Add 83.59%0.02%$115.39 - $144.01 $ 162.8125%156629
Joel Greenblatt 2014-09-30 Reduce -72.9%0.01%$115.39 - $144.01 $ 162.8125%2693
Ruane Cunniff 2014-09-30 New Buy$115.39 - $144.01 $ 162.8125%1617
John Hussman 2014-06-30 Reduce -66.67%0.93%$110.29 - $126.07 $ 162.8141%50000
Daniel Loeb 2014-06-30 New Buy0.65%$110.29 - $126.07 $ 162.8141%450000
Joel Greenblatt 2014-06-30 New Buy0.02%$110.29 - $126.07 $ 162.8141%9938
Mario Gabelli 2014-06-30 Add 85.28%0.02%$110.29 - $126.07 $ 162.8141%60335
Ken Fisher 2014-06-30 Add 71.02%0.01%$110.29 - $126.07 $ 162.8141%85316
PRIMECAP Management 2014-03-31 Reduce -9.42%0.46%$113.48 - $127.47 $ 162.8134%32161744
Vanguard Health Care Fund 2014-03-31 Reduce -6.4%0.2%$113.48 - $127.47 $ 162.8135%8213855
John Hussman 2014-03-31 Reduce -14.29%0.2%$113.48 - $127.47 $ 162.8135%150000
Joel Greenblatt 2014-03-31 Sold Out 0.06%$113.48 - $127.47 $ 162.8134%0
Ken Fisher 2014-03-31 Add 754.67%0.01%$113.48 - $127.47 $ 162.8135%49887
Mario Gabelli 2014-03-31 Add 37.87%0.01%$113.48 - $127.47 $ 162.8134%32565
Ray Dalio 2014-03-31 Sold Out 0.01%$113.48 - $127.47 $ 162.8134%0
Dodge & Cox 2014-03-31 Reduce -22.59%$113.48 - $127.47 $ 162.8134%105757
Vanguard Health Care Fund 2013-12-31 Reduce -18.43%0.76%$106.28 - $118.688 $ 162.8143%8775155
John Hussman 2013-12-31 Reduce -30%0.45%$106.28 - $118.688 $ 162.8143%175000
Joel Greenblatt 2013-12-31 New Buy0.06%$106.28 - $118.688 $ 162.8143%23170
Ray Dalio 2013-12-31 New Buy0.01%$106.28 - $118.688 $ 162.8143%7513
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.60
AMGN's P/E(ttm) is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 25.60 )
AMGN' s 10-Year P/E(ttm) Range
Min: 10.4   Max: 38.42
Current: 25.6

10.4
38.42
P/B 4.89
AMGN's P/B is ranked higher than
76% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. AMGN: 4.89 )
AMGN' s 10-Year P/B Range
Min: 1.8   Max: 5.24
Current: 4.89

1.8
5.24
P/S 6.34
AMGN's P/S is ranked higher than
87% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. AMGN: 6.34 )
AMGN' s 10-Year P/S Range
Min: 3.01   Max: 10.44
Current: 6.34

3.01
10.44
PFCF 17.70
AMGN's PFCF is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 17.70 )
AMGN' s 10-Year PFCF Range
Min: 8.78   Max: 49.8
Current: 17.7

8.78
49.8
EV-to-EBIT 21.75
AMGN's EV-to-EBIT is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 21.75 )
AMGN' s 10-Year EV-to-EBIT Range
Min: 8   Max: 27.5
Current: 21.75

8
27.5
PEG 2.94
AMGN's PEG is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 2.94 )
AMGN' s 10-Year PEG Range
Min: 0.25   Max: 2.89
Current: 2.94

0.25
2.89
Shiller P/E 29.54
AMGN's Shiller P/E is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 29.54 )
AMGN' s 10-Year Shiller P/E Range
Min: 12.72   Max: 80.07
Current: 29.54

12.72
80.07
Current Ratio 4.22
AMGN's Current Ratio is ranked higher than
71% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. AMGN: 4.22 )
AMGN' s 10-Year Current Ratio Range
Min: 1.31   Max: 6.33
Current: 4.22

1.31
6.33
Quick Ratio 3.88
AMGN's Quick Ratio is ranked higher than
70% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. AMGN: 3.88 )
AMGN' s 10-Year Quick Ratio Range
Min: 1.17   Max: 5.75
Current: 3.88

1.17
5.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.50
AMGN's Dividend Yield is ranked higher than
74% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. AMGN: 1.50 )
AMGN' s 10-Year Dividend Yield Range
Min: 0.48   Max: 1.89
Current: 1.5

0.48
1.89
Dividend Payout 0.36
AMGN's Dividend Payout is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 0.36 )
AMGN' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.56
Current: 0.36

0.22
0.56
Yield on cost (5-Year) 1.50
AMGN's Yield on cost (5-Year) is ranked higher than
68% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. AMGN: 1.50 )
AMGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.48   Max: 1.89
Current: 1.5

0.48
1.89
Share Buyback Rate 7.40
AMGN's Share Buyback Rate is ranked higher than
98% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. AMGN: 7.40 )
AMGN' s 10-Year Share Buyback Rate Range
Min: 8.3   Max: -7.5
Current: 7.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.23
AMGN's Price/DCF (Projected) is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 1.23 )
AMGN' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 6.23
Current: 1.23

0.59
6.23
Price/Median PS Value 1.46
AMGN's Price/Median PS Value is ranked higher than
80% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. AMGN: 1.46 )
AMGN' s 10-Year Price/Median PS Value Range
Min: 0.72   Max: 5.18
Current: 1.46

0.72
5.18
Price/Peter Lynch Fair Value 2.46
AMGN's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 2.46 )
AMGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.58   Max: 3.35
Current: 2.46

0.58
3.35
Earnings Yield (Greenblatt) 4.60
AMGN's Earnings Yield (Greenblatt) is ranked higher than
94% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. AMGN: 4.60 )
AMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 12.5
Current: 4.6

3.6
12.5
Forward Rate of Return (Yacktman) 13.51
AMGN's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. AMGN: 13.51 )
AMGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.5   Max: 70.3
Current: 13.51

1.5
70.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:AMG.Germany, 04332.Hongkong, AMGN34.Brazil, AMG N.Mexico, AMGN.Switzerland
Amgen Inc is a Delaware corporation was incorporated in 1980. The Company is a biotechnology medicines company. It discovers, develops, manufactures and delivers human therapeutics. Its medicines help patients fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. The Company operates in one business segment which includes human therapeutics. Its products are Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, XGEVA, Prolia and Sensipar/Mimpara. The products it manufactures include both biologics and small molecule drugs. The majority of its products are biologics which are produced in living systems and are inherently complex due to naturally-occurring molecular variations. In addition to its marketed products, it has various product candidates in mid- to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company competes with other clinical trials for eligible patients, which may limit the number of available patients who meet the criteria for certain clinical trials.
» More Articles for NAS:AMGN

Headlines

Articles On GuruFocus.com
Amgen: Stronger Drug Portfolio with Acquisition Oct 28 2014 
Daniel Loeb Comments on Amgen Inc Oct 22 2014 
Third Point Q3 2014 Investor Letter Oct 22 2014 
Amgen: Stronger Drug Portfolio with Acquisition Sep 22 2014 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
You Can No Longer Ignore Biotech Feb 07 2014 


More From Other Websites
Motley Fool: Pundits pandering your wealth away Nov 22 2014
Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Nov 21 2014
Fighting kids' cancer... fixing a broken system Nov 21 2014
New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
SINGAPORE PRESS-Amgen opens S$200 mln plant in Singapore-Straits Times Nov 20 2014
Amgen Opens Next-generation Biomanufacturing Facility in Singapore Nov 19 2014
Amgen Inc Conference Call to Discuss Evolocumab Development Program at AHA scheduled for 7:00 pm ET... Nov 18 2014
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering... Nov 18 2014
Amarantus unterzeichnet exklusive Optionsvereinbarung zum Erwerb eines gezüchteten Hautersatzes... Nov 17 2014
Merck Drug Works: Vytorin Study Proves Successful Nov 17 2014
3 Stocks Moving The Drugs Industry Upward Nov 17 2014
IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe Nov 17 2014
At the American Heart Association Meeting You Really Can't Escape The New Cholesterol Drugs Nov 15 2014
Biotech correction coming? 16 trades, 55 seconds Nov 14 2014
Amgen To Present At The Jefferies Global Healthcare Conference Nov 14 2014
Amgen To Present At The Jefferies Global Healthcare Conference Nov 14 2014
Jana in third quarter took new stake in Valeant, upped stake in eBay Nov 14 2014
Window into 13F filings Nov 14 2014
Which Health Care ETF Should You Buy? Nov 13 2014
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK